Secondary Stock OfferingsBy The Online Investor Staff, updated Fri., Jan. 24, 6:31 PM
|This Slide: #2 of 25|
Slide #2. Autolus Therapeutics plc — Secondary Offering
Autolus Therapeutics plc (NASDAQ:AUTL)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 7,250,000 American Depositary Shares ("ADSs") representing 7,250,000 ordinary shares at a public offering price of $11.00 per ADS, for total gross proceeds of approximately $80.0 million. All ADSs sold in the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 1,087,500 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 27, 2020, subject to customary closing conditions.
Autolus Therapeutics is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using Co.'s broad suite of proprietary and modular T cell programming technologies, Co. is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.
Open the AUTL Page at The Online Investor »
Strong Buy (3.80 out of 4)
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite